Tolvaptan promotes the excretion of electrolyte‐free water, known as aquaresis, and is authorized for the treatment of hyponatraemia due to the syndrome of inappropriate antidiuretic hormone secretion (SIAD), a common cause of hyponatraemia. Here, AVP is linked to Hyponatremia.